Experience the new reality
Beacon Medical Australia is committed to ensuring we produce the highest quality cannabinoid medicines to meet patients’ needs.Keep scrolling down to explore what we’re all about
Beacon Medical’s parent company is the Canadian-listed VIVO Cannabis who have been growing and selling pharmaceutical-grade medical cannabis to medical patients in a “quality-first” culture since 2014. Our subsidiary Canna Farms was the first producer in British Columbia, Canada to be licensed by Health Canada. Our subsidiary ABcann Medicinals has been producing pharmaceutical-grade medical cannabis in Ontario, Canada since 2016. Our subsidiary Harvest Medicine has seen tens of thousands of medical cannabis patients.
Our state-of-the-art indoor growing facilities are precision controlled environments and some of the most technologically advanced in the world. We manipulate the key plant growth variables for each strain to ensure we consistently produce the highest quality products for patient’s needs.
We know Science Matters
We have taken the art of producing Cannabis and turned it into a science of precision.Our exclusive Cannabis R&D partnership with the University of Guelph ensures that we will continue to remain on the cutting edge of Cannabis cultivation science. Our research agreements with other academic institutions, physicians and pharmaceutical partners ensures that we will remain at the forefront of developing new cannabinoid therapeutics and growing the understanding of how medicinal cannabis can be used to improve patient’s lives.
VIVO provides pharmaceutical grade medicinal cannabis products to medical patients through its subsidiary Beacon Medical and is committed to working with physicians to provide cannabinoid therapeutics to patients. We produce pharmaceutical-grade medicinal cannabis flowers for vaporization, oils for ingestion and continue to develop dosing forms to improve patient outcomes.
About Medicinal Cannabis
Cannabis has been used by people to treat disease and illness for more than five-thousands years.
Cannabis plants produce many compounds that are active in the body including a family of compounds called the Cannabinoids. These compounds, including ones you may have heard of such as THC and CBD interact with receptors in the body's endocannabinoid system Medical Cannabis imparts its effects through this natural system.
- THC causes the ‘high’ feeling associated with Cannabis use, but it has also been found to help patients experiencing pain, muscle spasms, nausea, vomiting, and other conditions.
- CBD can help reduce the ‘high’ caused by THC and has been found to be effective for some patients suffering seizures, inflammation and anxiety.
Cannabinoids such as THC and/or CBD have been used by patients suffering from a range of diseases.
Our medical cannabis plants and the medicines we make from them are produced under strictly controlled conditions. These conditions ensure patients receive a consistent, high quality product, that is free from heavy metals, pesticides and other contaminants which could cause adverse health effects and can be found in illicit cannabis products.
The Endocannabinoid System
The endocannabinoid system is found throughout the body; in the central nervous system, internal organs, connective tissues, glands and immune cells and is responsible for maintaining the body in a state of homeostasis (“relax, eat, sleep, forget, protect”).
Despite its pervasiveness (the CB1 receptor is the most abundant G-Protein coupled receptor (GPCR) in the mammalian brain ), the system's discovery has occurred relatively recently; and it is only now that the potential of cannabinoid therapeutics are starting to be fully explored and appreciated.
Endocannabinoid Discovery Timeline
CB1 receptor identified
Endocannabinoid Anandamide (N-arachidonoylethanolamine) identified
CB2 receptor identified
Endocannabinoid 2-AG (2-arachidonoylglycerol) identified
Cannabinoid receptors only show low-levels of expression in the primary motor cortex . This combined with their ability to closely interact with the master-regulatory endocannabinoid system may explain why the administration of cannabinoids has been reported as having therapeutic benefits for patients across a range of debilitating diseases.
Beacon’s pharmaceutical heritage means that we implicitly understand the need for consistent, pharmaceutical grade Medicinal cannabis products for the administration to patients.
Adam Pirie PhD (Pharm. Pharmaceut. Sci.)
Director Operations-Beacon Medical Australia
Over 10 years experience in the leadership and management of complex projects. Experience working in regulatory for large, multi-national pharma; in technology assessment; and early-stage biotech, guiding lead compounds from the pre-clinical to first-in-human phase I.
Track record of building sustainable businesses and executing growth strategy
Get In Touch
Beacon Medical Australia